DEFENCE THERAPEUTICS A - DTCFF STOCK NEWS

Defence Therapeutics announced the publication of a peer-reviewed study on AccuTOX, an anti-cancer molecule, in the Journal of Translational Medicine. The study details how AccuTOX synergizes with immune-checkpoint inhibitors to disrupt tumor growth. AccuTOX, derived from the Accum platform, shows enhanced killing potency, versatility, and ease of manufacturing. It induces immunogenic cell death and enhances cancer cell visibility to the immune system. The compound targets multiple cancer cell lines and has shown no apparent toxicity in animal models. Defence is initiating a Phase I trial and has submitted a CTA application to Health Canada.

Defence Therapeutics, a biopharmaceutical firm, announced the issuance and allowance of multiple patents across several Patent Families. The US Patent Office allowed application no. 18/169,440, enhancing the company's vaccine platform technology, Accum®, known for boosting antigen presentation. Recent pre-clinical studies using Defence's ARM-002™ vaccine showed significant antitumor responses, paving the way for Phase I trials.

Another patent in Australia for Defence's ADC platform was granted on February 1, 2024, further protecting Accum® and its variants, and adding to existing patents in the US, Japan, and Israel. Additionally, patents for Defence's vaccine platform technology were granted in Canada and Australia, with a Japanese patent expected soon. These patents cover methods and compositions for enhancing antigen immunogenicity.

CEO Mr. Plouffe highlighted the importance of these patents in Defence's mission to innovate and improve human health. The company is accelerating the examination of remaining applications via the Patent Prosecution Highway (PPH) program.

Defence Therapeutics Inc. announces successful completion of a pre-clinical vaccination trial using its ARM-002TM vaccine against pancreatic cancer, showing therapeutic effectiveness when combined with an immune-checkpoint inhibitor. Results reveal potent vaccine efficacy with tumor growth inhibition, positioning the company to target 'hard-to-treat' cancers like pancreatic cancer. The pancreatic cancer market is projected to exceed USD 36 billion by 2036.

Defence Therapeutics Inc. announces the success of its second-generation ARMTM anti-cancer vaccine, ARM-002TM, which has shown therapeutic effectiveness against pre-established melanoma when combined with an immune-checkpoint inhibitor. The vaccine utilizes AccuTOX® to induce protein aggregation in mesenchymal stromal cells, leading to potent antigen presentation. ARM-002TM is more potent than its predecessor, requiring 10x less protein for similar outcomes in both in vitro and in vivo studies. The vaccine is being tested on 'hard-to-treat' cancers like pancreatic, colon, and ovarian cancers, showing promising versatility and adaptability.

Defence Therapeutics partners with FMS Consult GmbH for financing strategy to support pipeline growth. The company's Accum® platform shows promise in cancer treatment.

Defence Therapeutics Inc. announces an amendment to the terms of 1,497,780 Class A Common share purchase warrants, extending the expiry date by 12 months and repricing the exercise price at $1.75 per share.

Defence Therapeutics Inc. announces successful testing of second-generation anti-cancer vaccine ARM-002TM with promising results in melanoma model. The vaccine shows an 80% complete response rate when combined with anti-PD-1 immune-checkpoint inhibitor. Defence reprogrammed MSCs using AccuTOX® to create a potent antigen presenting cell vaccine, reducing antigen preparation challenges. The company plans to expand testing to ovarian and pancreatic cancers and initiate Phase I trials targeting solid tumors.

Defence Therapeutics Inc. announces the closing of the 2nd tranche of its non-brokered private placement, raising $600,000 for advancing preclinical and clinical programs.

Defence Therapeutics Inc. receives US patent for its breakthrough AccuTOX technology, providing market exclusivity until 2042. The technology induces cancer cell death and shows promising results in pre-clinical studies, leading to FDA approval for Phase I clinical trials in melanoma patients.